Tumor DNA Testing for Upper Tract Urothelial Carcinoma
Circulating and Urine Tumor DNA Dynamics Predict Minimal Residual Disease and Recurrence Risk in Locally Advanced Upper Tract Urothelial Carcinoma
Recruiting
Observational Study
Muscle Invasive Upper Tract Urothelial Carcinoma
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Study type
- Observational
- Participants needed
- 84 (estimated)
- Sponsor
- RenJi Hospital · Other
Who this trial is looking for
This trial is looking for patients with a specific type of cancer in the upper urinary tract. Participants will provide blood and urine samples to help doctors learn more about the disease and its treatment.
Are You a Good Fit for This Trial?
You may be able to join if
- I am at least 18 years old
- I have been diagnosed with upper tract urothelial carcinoma
- I have not had cancer spread to other parts of my body
- I have had surgery to remove my tumor
- I am willing to undergo additional tests after surgery
- I have not been diagnosed with multiple cancers
- I have received chemotherapy or immunotherapy within the last 12 weeks
- I have a performance status score of 0 to 2
You may not be able to join if
- I have a history of bladder cancer
- I am pregnant or breastfeeding
- I have a severe infection
- I have severe heart disease
- I have uncontrolled neurological or mental disorders
- I have severe diabetes
- I have severe autoimmune diseases
- I have had neoadjuvant therapy
Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
In our study, the ultra-deep sequencing of circulating tumor DNA (ctDNA) and urine tumor DNA (utDNA) were performed to assess whether ctDNA and utDNA can be used as predictive biomarkers for the detection of minimal residual disease (MRD) and early diagnosis of UTUC recurrence, and explored the role of ctDNA and utDNA detection of MRD in the prediction of adjuvant therapy efficacy and prognostic e…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* pathological comfirmed T2-4 or N+ and M0 upper tract urothelial carcinoma
* Male or female aged ≥18 years old who are willing to sign the informed consent form
* have no distant metastasis
* have an ECOG 0 to 2
* upper tract urothelial carcinoma patients received radical nephr…
Contacts